Jazz Pharmaceuticals, Inc. (JAZZ)
Health Care ยท Pharmaceutical Preparations
Jazz Pharmaceuticals, Inc. (JAZZ) is listed on Nasdaq, where its shares have traded since June 1, 2007. SentiSense covers Jazz Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Renee Gala is its chief executive officer. The company reports 2,890 employees, and its corporate website is www.jazzpharmaceuticals.com.
About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Latest reported results
Jazz Pharmaceuticals plc reported revenue of $1.21 billion for Q2 FY2026, up 15.5% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 631 institutions reported holding JAZZ, with 64.2 million shares worth $15.5 billion in aggregate. The largest reported holders were Vanguard, BlackRock and FMR. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on JAZZ
- JAZZ sentiment: whether news and social coverage of Jazz Pharmaceuticals, Inc. leans bullish or bearish, and the stories driving it.
- JAZZ ownership: all 631 reporting institutions, plus insider and congressional trades.
- JAZZ financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for Jazz Pharmaceuticals, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Jazz Pharmaceuticals, Inc. do?
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology.
What sector is JAZZ in?
SentiSense classifies Jazz Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does JAZZ stock trade?
Jazz Pharmaceuticals, Inc. (JAZZ) is listed on Nasdaq, where its shares have traded since June 1, 2007.
Who is the CEO of Jazz Pharmaceuticals, Inc.?
Renee Gala is the chief executive officer of Jazz Pharmaceuticals, Inc..